LPV/r + TDF (n=72) LPV/r + 2 NRTIs (n=80) D/C before Week 24 8 (11.1%) 6 (7.5%)   Fever, headache, rash     Headache, diarrhea     Nausea, vomiting, GI pain     Diarrhoea     Diarrhoea, vomiting     Nausea, vomiting     Dyspnea, chest pain (death)   D/C after Week 24 3 (4.2%) 0   Increase in transaminases     Suspect lymphoproliferative disorder (death)     Dizziness, nausea, vomiting   D/C, discontinuation, LPV/r, Lopinavir/ritonavir; NRTI, Nucleoside Reverse Transcriptase Inhibitor; TDF, Tenofovir Disoproxyl Fumarate.

Table 3: Adverse events leading to discontinuation. Data on Adverse events given as primary reason for discontinuation are presented.